ES2572481T3 - Derivado de triacina y composición farmacéutica que tiene una actividad analgésica que contiene la misma - Google Patents

Derivado de triacina y composición farmacéutica que tiene una actividad analgésica que contiene la misma

Info

Publication number
ES2572481T3
ES2572481T3 ES11816413T ES11816413T ES2572481T3 ES 2572481 T3 ES2572481 T3 ES 2572481T3 ES 11816413 T ES11816413 T ES 11816413T ES 11816413 T ES11816413 T ES 11816413T ES 2572481 T3 ES2572481 T3 ES 2572481T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
substituents
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11816413T
Other languages
English (en)
Inventor
Hiroyuki Kai
Takayuki Kameyama
Tohru Horiguchi
Kentaro Asahi
Takeshi Endoh
Yasuhiko Fujii
Takuya Shintani
Ken'ichiroh Nakamura
Sae Jikihara
Tsuyoshi Hasegawa
Miho Oohara
Yukio Tada
Toshikatsu Maki
Akira Iida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2572481T3 publication Critical patent/ES2572481T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula (VIII):**Fórmula** en el que Z1 y Z2 son cada uno independientemente un átomo de oxígeno, un átomo de azufre o >=N-Rx; Rx es un átomo de hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, un grupo heterocíclico no aromático sustituido o no sustituido, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; Rc es un átomo de hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, acilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, un grupo heterocíclico no aromático sustituido o no sustituido, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; R4a y R4b son cada uno independientemente un átomo de hidrógeno o alquilo sustituido o no sustituido, o R4a y R4b ligados al mismo átomo de carbono se toman juntos para formar oxo o tioxo; n es un número entero de 1 a 4; R2 es cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, un grupo heterocíclico no aromático sustituido o no sustituido, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; -X- es -O-, -S-, -N(R5)- o (CR5aR5b)-; -L- es -O-, -S-, -N(R5')- o -(CR5a'-R5b')-; R5 y R5' son cada uno independientemente un átomo de hidrógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, o acilo sustituido o no sustituido; R5a, R5b, R6a' y R5b' son cada uno independientemente un átomo de hidrógeno, halógeno, hidroxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alquiloxi sustituido o no sustituido, alquiniloxi sustituido o no sustituido o alqueniloxi sustituido o no sustituido; el anillo D es un anillo de benceno, un anillo de piridina, un anillo de pirimidina, un anillo de piracina o un anillo de piridacina; el átomo de carbono a y el átomo de carbono b son átomos de carbono que constituyen el anillo D; el anillo B es un anillo heterocíclico aromático; s y s' son cada uno independientemente un número entero de 0 a 3; y R9 y R9' son cada uno independientemente halógeno, hidroxi, carboxi, ciano, nitro, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, alquiloxi sustituido o no sustituido, alqueniloxi sustituido o no sustituido, alquiniloxi sustituido o no sustituido, alquiltio sustituido o no sustituido, alqueniltio sustituido o no sustituido, alquiniltio sustituido o no sustituido, acilo sustituido o no sustituido, alquiloxicarbonilo sustituido o no sustituido, alqueniloxicarbonilo sustituido o no sustituido, alquiniloxicarbonilo sustituido o no sustituido, carbamoílo sustituido o no sustituido, amino sustituido o no sustituido, sulfamoílo sustituido o no sustituido, sulfonilo sustituido, sulfinilo sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, un grupo heterocíclico no aromático sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquiloxi sustituido o no sustituido, cicloalqueniloxi sustituido o no sustituido, heterocicliloxi no aromático sustituido o no sustituido, ariloxi sustituido o no sustituido o heteroariloxi sustituido o no sustituido; o su sal farmacéuticamente aceptable o un solvato del mismo, en donde sustituyentes permisibles para "alquilo sustituido", "alquenilo sustituido", "alquinilo sustituido", "alquiloxi sustituido", "alqueniloxi sustituido", "alquiniloxi sustituido ", "alquiltio sustituido", "alqueniltio sustituido ", "alquiniltio sustituido", "alquiloxicarbonilo sustituido", "alqueniloxicarbonilo sustituido" y "alquiniloxicarbonilo sustituido" incluyen uno o más sustituyentes iguales o diferentes seleccionados del grupo que consiste en: hidroxi, carboxi, halógeno, haloalquiloxi, cicloalquilo, cicloalquenilo, metoxi, etoxi, propoxi, butoxi, alqueniloxi, alquiloxicarbonilo, nitro, nitroso, amino, alquilamino, acilamino, arilalquilamino, hidroxiamino, alquilsulfonilamino, alquilsulfinilamino, imino, hidroxiimino, alquilimino, alquiloxiimino, acilimino, azido, arilo, arilalquilo, arilalquiloxi, un grupo heterocíclico no aromático, heteroarilo, heteroarilalquilo, ciano, isociano, isocianato, tiocianato, isotiocianato, mercapto, alquiltio, alquilsulfonilo, carbamoílo, alquilcarbamoílo, sulfamoílo, alquilsulfamoílo, acilo, formiloxi, tioformilo, tiocarboxi, ditiocarboxi, tiocarbamoílo, sulfino, sulfo, hidracino, azido, ureido, amidino, guanidino, ftalimido, trialquilsililo y oxo, sustituyentes para "acilo sustituido" se seleccionan de los sustituyentes que se definen anteriormente para "alquilo sustituido", un grupo hidrocarbonado monovalente de cadena lineal o ramificada de un número de carbonos de 1 a 15, un alquenilo lineal o ramificado de un número de carbonos de 2 a 15 y un alquinilo lineal o ramificado de un número de carbonos de 2 a 15, si R en el acilo (R-C(>=O)-) es cicloalquilo, cicloalquenilo, un grupo heterocíclico no aromático, arilo o heteroarilo, entonces cada anillo puede estar sustituido con alquilo, haloalquilo, alquenilo, alquinilo, alquiloxi, halógeno, sustituyentes para "carbamoílo sustituido" y "sulfamoílo sustituido" son uno o más grupos iguales o diferentes seleccionados del grupo que consiste en: hidroxi, carboxi, halógeno, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, alquiloxicarbonilo, amino, alquilamino, acilamino, arilalquilamino, hidroxiamino, arilo, ciano, isociano, isocianato, tiocianato, isotiocianato y acilo, sustituyentes para "amino sustituido" son uno o más grupos iguales o diferentes seleccionados del grupo que consiste en: alquilo, haloalquilo, hidroxialquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, alquiloxi, haloalquiloxi, alqueniloxi, alquiloxicarbonilo, alquiloxicarbonilalquilo, amino, alquilamino, acilamino, arilalquilamino, hidroxiamino, imino, hidroxiimino, alquilimino, alquiloxiimino, acilimino, arilo, arilalquilo, ariloxi, un grupo heterocíclico no aromático, heteroarilo, heteroarilalquilo, heterocicliloxi no aromático, heteroariloxi, hidroxi, halógeno, ciano, acilo, alquilsulfonilo, alquilsulfinilo, carbamoílo, alquilcarbamoílo, alquilcarbamoilalquilo, carbamoilalquilo, carboxialquilo, sulfamoílo, alquilsulfamoílo, alquilsulfamoilalquilo y sulfamoilalquilo, sustituyentes para "cicloalquilo sustituido", "cicloalquenilo sustituido", "arilo sustituido", "heteroarilo sustituido" y "un grupo heterocíclico no aromático sustituido" son uno o más grupos iguales o diferentes seleccionados del grupo que consiste en: alquilo, haloalquilo, haloalquiloxi, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, alquiloxi, alqueniloxi, alquiloxicarbonilo, nitro, nitroso, amino, alquilamino, acilamino, arilalquilamino, hidroxiamino, amino sustituido con uno o dos sustituyentes iguales o diferentes seleccionados del Grupo de Sustituyentes Y mencionado posteriormente, imino, hidroxiimino, alquilimino, alquiloxiimino, acilimino, azido, arilo, arilalquilo, carbocicliloxi no aromático no sustituido, carbocicliloxi no aromático sustituido con uno o más sustituyentes iguales o diferentes seleccionados del Grupo de Sustituyentes Z mencionado posteriormente, carbociclilalquiloxi no aromático no sustituido, carbociclilalquiloxi no aromático sustituido con uno o más sustituyentes iguales o diferentes seleccionados del Grupo de Sustituyentes Z mencionado posteriormente, ariloxi no sustituido, ariloxi sustituido con uno o más sustituyentes iguales o diferentes seleccionados del Grupo de Sustituyentes Z mencionado posteriormente, arilalquiloxi no sustituido, arilalquiloxi sustituido con uno o más sustituyentes iguales o diferentes seleccionados del Grupo de Sustituyentes Z mencionado posteriormente, un grupo heterocíclico no aromático, heteroarilo, heteroarilalquilo, heterocicliloxi no aromático no sustituido, heterocicliloxi no aromático sustituido con uno o más sustituyentes iguales o diferentes seleccionados del Grupo de Sustituyentes Z mencionado posteriormente, heteroariloxi no sustituido, heteroariloxi sustituido con uno o más sustituyentes iguales o diferentes seleccionados del Grupo de Sustituyentes Z mencionado posteriormente, ciano, isociano, isocianato, tiocianato, isotiocianato, mercapto, alquiltio, alquilsulfonilo, carbamoílo sustituido o no sustituido, alquilcarbamoílo sustituido o no sustituido, sulfamoílo, alquilsulfamoílo, hidroxi, carboxi, halógeno, acilo, formiloxi, tioformilo, tiocarboxi, ditiocarboxi, tiocarbamoílo, sulfino, sulfo, hidracino, azido, ureido, amidino, guanidino, ftalimido y oxo, un Grupo de Sustituyentes Y incluye hidroxialquilo, alquiloxicarbonilo, alquiloxicarbonilalquilo, alquilsulfonilo, alquilsulfinilo, carbamoílo, alquilcarbamoílo, alquilcarbamoilalquilo, carbamoilalquilo, carboxialquilo, sulfamoílo, alquilsulfamoílo, alquilsulfamoilalquilo y sulfamoilalquilo, un Grupo de Sustituyentes Z incluye halógeno, hidroxi, carboxi, ciano, nitro, alquilo, hidroxialquilo, aminoalquilo, alquilaminoalquilo, alquenilo, alquinilo, alquiloxi, alqueniloxi, alquiniloxi, alquiltio, alqueniltio, alquiniltio, acilo, alquiloxicarbonilo, alqueniloxicarbonilo, alquiniloxicarbonilo, carbamoílo, alquilcarbamoílo, haloalquilcarbamoílo, hidroxialquilcarbamoílo, cianocarbamoílo, amino, acilamino, amino sustituido con uno o dos sustituyentes iguales o diferentes seleccionados del Grupo de Sustituyentes Y anterior, sulfamoílo, metilsulfonilo, metilsulfinilo, cicloalquilo, cicloalquenilo, un grupo heterocíclico no aromático, arilo, heteroarilo, cicloalquiloxi, cicloalqueniloxi, heterocicliloxi no aromático, ariloxi y heteroariloxi.
ES11816413T 2010-08-10 2011-08-09 Derivado de triacina y composición farmacéutica que tiene una actividad analgésica que contiene la misma Active ES2572481T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010179350 2010-08-10
JP2010182803 2010-08-18
JP2011074763 2011-03-30
PCT/JP2011/068113 WO2012020749A1 (ja) 2010-08-10 2011-08-09 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物

Publications (1)

Publication Number Publication Date
ES2572481T3 true ES2572481T3 (es) 2016-05-31

Family

ID=45567712

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11816413T Active ES2572481T3 (es) 2010-08-10 2011-08-09 Derivado de triacina y composición farmacéutica que tiene una actividad analgésica que contiene la misma

Country Status (16)

Country Link
US (1) US9718790B2 (es)
EP (1) EP2604595B1 (es)
JP (2) JP5594706B2 (es)
KR (1) KR101867110B1 (es)
CN (1) CN103153968B (es)
AU (1) AU2011290261B2 (es)
BR (1) BR112013002984B1 (es)
CA (1) CA2807947C (es)
DK (1) DK2604595T3 (es)
ES (1) ES2572481T3 (es)
MX (1) MX346367B (es)
PL (1) PL2604595T3 (es)
RU (1) RU2565073C2 (es)
TW (2) TWI505829B (es)
WO (1) WO2012020749A1 (es)
ZA (1) ZA201300920B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
WO2012006004A1 (en) * 2010-06-28 2012-01-12 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists for the treatment of pain
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
CN103153968B (zh) 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
TW201331188A (zh) * 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
WO2013118855A1 (ja) * 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
JP6304492B2 (ja) * 2012-03-30 2018-04-04 日産化学工業株式会社 トリアジノン化合物及びｔ型カルシウムチャネル阻害剤
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
EP3670496A3 (en) * 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
WO2015099107A1 (ja) * 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
JPWO2016084922A1 (ja) * 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
US10774051B2 (en) 2015-04-24 2020-09-15 Shionogi & Co., Ltd. 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same
WO2018074390A1 (ja) 2016-10-17 2018-04-26 塩野義製薬株式会社 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
GB201810669D0 (en) * 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
ES2963702T3 (es) 2018-10-05 2024-04-01 Shionogi & Co Medicina para tratar la tos crónica
TWI889708B (zh) 2019-09-19 2025-07-11 日商塩野義製藥股份有限公司 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
CN118286233A (zh) 2019-10-02 2024-07-05 Aska制药株式会社 排尿障碍改善剂
WO2021065027A1 (ja) 2019-10-02 2021-04-08 あすか製薬株式会社 排尿障害改善剤
TW202203929A (zh) 2020-04-03 2022-02-01 日商塩野義製藥股份有限公司 疼痛治療用醫藥
WO2022105852A1 (zh) * 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
US20240041899A1 (en) 2020-12-18 2024-02-08 Aska Pharmaceutical Co., Ltd. Solid preparation
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
US20240287026A1 (en) * 2021-06-04 2024-08-29 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Triazinylmethylcycloalkylcarboxylic acid derivative, and pharmaceutical composition and use thereof
CN113773300B (zh) * 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
CN113801097B (zh) * 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113620888B (zh) * 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和应用
WO2023054292A1 (ja) 2021-09-28 2023-04-06 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
AU2022353486A1 (en) 2021-09-28 2024-05-02 National University Corporation Hokkaido University Pharmaceutical composition containing triazine derivative
EP4289432A4 (en) 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
CN116514734A (zh) * 2021-11-24 2023-08-01 盐野义制药株式会社 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
JP7261529B1 (ja) 2021-11-24 2023-04-20 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
US20250025459A1 (en) * 2021-11-26 2025-01-23 Shionogi & Co., Ltd. Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
WO2023054732A2 (ja) 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
CN116730988A (zh) * 2022-03-10 2023-09-12 湖北九康通生物医药有限公司 一种三嗪类化合物、其中间体、其制备方法及其用途
CN116284133B (zh) * 2022-03-24 2024-03-29 南京知和医药科技有限公司 一种新型六元杂环类衍生物及其药物组合物和用途
US11655240B1 (en) * 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
WO2023184482A1 (zh) * 2022-04-01 2023-10-05 湖南南新制药股份有限公司 氨基三嗪酮化合物及其制备方法和药物用途
WO2023193818A1 (zh) * 2022-04-08 2023-10-12 湖北九康通生物医药有限公司 一种多取代三嗪烷类化合物的合成方法
CN114805314B (zh) * 2022-04-20 2023-12-15 杭州国瑞生物科技有限公司 一种恩赛特韦的合成方法
CN114751894A (zh) * 2022-04-29 2022-07-15 苏州立新制药有限公司 一种治疗新冠肺炎口服药物的制备方法
CN115650959B (zh) * 2022-05-20 2023-10-20 南京济群医药科技股份有限公司 化合物的制备方法或纯化方法
CN114773282B (zh) * 2022-05-27 2024-07-02 杭州布朗生物医药科技有限公司 3-叔丁基-6-乙硫基-1,3,5-三嗪-2,4(1h,3h)-二酮的制备方法
CN115504968B (zh) 2022-11-21 2023-04-18 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN120303259A (zh) * 2022-11-30 2025-07-11 上海海雁医药科技有限公司 取代的三嗪-2,4-二酮类衍生物中间体及其制备方法
WO2024114663A1 (zh) * 2022-11-30 2024-06-06 上海海雁医药科技有限公司 三嗪基甲基环烷基羧酸衍生物的晶型及其应用
WO2024169781A1 (zh) * 2023-02-15 2024-08-22 南京明德新药研发有限公司 嘧啶酮衍生物及其在药学上的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598815A (en) * 1968-10-25 1971-08-10 Goodrich Co B F Bis-(hydroxyphenylalkylene) alkyl isocyanurates
JPS5132324A (en) * 1974-09-12 1976-03-18 Fuji Photo Film Co Ltd Netsugenzokankozairyo
CH622536A5 (es) 1976-07-08 1981-04-15 Ciba Geigy Ag
US4158724A (en) 1976-10-18 1979-06-19 Ciba-Geigy Corporation Tris-tetrazoles as chemical blowing agents
CH623840A5 (es) * 1976-10-18 1981-06-30 Ciba Geigy Ag
GB1599518A (en) 1977-02-21 1981-10-07 Ici Ltd 1,3,5-triazine-2,6-diones and pharmaceutical compositions thereof
ATE698T1 (de) 1978-05-26 1982-03-15 Imperial Chemical Industries Plc Analgetische 6-acylaminot etrahydro-1,3,5-triazin-2,4-dion-derivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.
JPS57144269A (en) 1981-03-03 1982-09-06 Taiho Yakuhin Kogyo Kk Triazine derivative and its preparation
EP0110828B1 (de) * 1982-11-26 1988-01-20 Ciba-Geigy Ag Farbphotographisches Aufzeichnungsmaterial
JPS62156110A (ja) 1985-12-27 1987-07-11 Res Inst For Prod Dev 測鎖にイソシアヌレ−ト構造を含む吸着能力を有する重合体
ATE111911T1 (de) 1989-06-05 1994-10-15 Daiichi Seiyaku Co Heterocyclische triazin- oder triazolo- verbindungen mit serotonin 2-rezeptor- antagonisten-wirkung.
RU2057754C1 (ru) 1989-06-05 1996-04-10 Дайити Фармасьютикал Ко., Лтд. Гетероциклические соединения или их кислотно-аддитивные соли
DE4141721A1 (de) 1991-12-18 1993-06-24 Bayer Ag Substituierte heterocyclyltriazindione
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
WO1999052881A1 (en) 1998-04-15 1999-10-21 Sagami Chemical Research Center 2-anilinopyrimidinone derivatives, intermediates in the production thereof, process for producing the same and pesticides containing the same as the active ingredient
JP2995293B1 (ja) 1998-08-25 1999-12-27 工業技術院長 １，６‐ジ置換‐１，３，５‐トリアジン‐２，４（１ｈ，３ｈ）‐ジオン化合物の製造方法
US6177437B1 (en) 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6713486B1 (en) 1999-03-04 2004-03-30 Korea Research Institute Of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
JP4674676B2 (ja) 1999-11-08 2011-04-20 公益財団法人相模中央化学研究所 ２−置換アミノピリミジノン誘導体、それらの製造方法並びにそれらを有効成分とする殺虫、殺ダニ剤
AU2001227084A1 (en) 2000-01-25 2001-08-07 Japan Tobacco Inc. N-arylhydrazide compounds and use thereof as drugs
US20020049320A1 (en) 2000-04-27 2002-04-25 American Cyanamid Company 6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof
DK1392643T3 (da) 2001-05-18 2006-01-30 Abbott Lab (1S)-1,2,3,4-tetrahydro-1-naphthalenylbenzamider, der er trisubstituerede ved N, og som inhiberer receptorer indeholdende P2X3 og P2X2/3
JPWO2004054617A1 (ja) 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
WO2005009980A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
CA2557372C (en) 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
JP2008507368A (ja) 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー 肺疾患を診断、モニタリングおよび治療するための方法
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
EP1869006A1 (en) * 2005-03-24 2007-12-26 Janssen Pharmaceutica N.V. Pyrimidindione derivatives as prokineticin 2 receptor antagonists
KR20080006564A (ko) 2005-03-24 2008-01-16 얀센 파마슈티카 엔.브이. 프로키네티신 1 수용체 길항제
JP2008537548A (ja) 2005-03-24 2008-09-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ プロキネチシン１受容体
US8507415B2 (en) 2005-05-03 2013-08-13 Southwest Research Institute Lubricant oils and greases containing nanoparticle additives
MX2007013595A (es) 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
MX2008002014A (es) 2005-08-15 2008-03-27 Hoffmann La Roche Derivados de piperidina y piperazina como antagonistas de p2x3.
CN101300012B (zh) 2005-09-01 2011-09-14 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用
MX2008002731A (es) 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores de p2x3 y p3x2/3.
EP1924564B1 (en) 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
WO2007079163A2 (en) 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
CA2635845A1 (en) 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 2 receptor antagonists
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
KR20110089463A (ko) 2006-07-24 2011-08-08 한국화학연구원 신규 ｈｉｖ 역전사 효소 억제제
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
WO2008127591A2 (en) 2007-04-13 2008-10-23 Schering Corporation Pyrimidinedione derivatives and use thereof
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2009007258A (ja) 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd Ｐａｉ−１産生抑制作用を有する３−アニリノ−２−シクロアルケノン誘導体
JP2011502154A (ja) * 2007-10-30 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノヘテロアリールを含むプロキネチシン１受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。
KR20100124262A (ko) 2008-02-13 2010-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 비시클로아민 유도체
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
MX2011004570A (es) * 2008-10-31 2011-06-17 Merck Sharp & Dohme Antagonistas del receptor p2x3 para el tratamiento del dolor.
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
SG177308A1 (en) 2009-06-22 2012-02-28 Hoffmann La Roche Novel biphenyl and phenyl-pyridine amides
MX2012001646A (es) 2009-08-05 2012-03-21 Du Pont Pesticidas mesoionicos.
CA2806572C (en) 2010-07-30 2018-10-30 Expression Pathology, Inc. C-src selected reaction monitoring assay
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
CN103153968B (zh) 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
JP5849246B2 (ja) 2010-09-03 2016-01-27 パナソニックＩｐマネジメント株式会社 スクロール圧縮機
ES2759615T3 (es) 2011-04-01 2020-05-11 Univ Utah Res Found Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
TW201331188A (zh) 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物

Also Published As

Publication number Publication date
JP5594706B2 (ja) 2014-09-24
US20130172317A1 (en) 2013-07-04
EP2604595B1 (en) 2016-03-16
RU2013110068A (ru) 2014-09-20
TW201542210A (zh) 2015-11-16
KR101867110B1 (ko) 2018-06-12
AU2011290261A1 (en) 2013-03-07
PL2604595T3 (pl) 2016-09-30
RU2565073C2 (ru) 2015-10-20
TWI505829B (zh) 2015-11-01
KR20130138734A (ko) 2013-12-19
TW201210600A (en) 2012-03-16
BR112013002984A2 (pt) 2016-06-07
US9718790B2 (en) 2017-08-01
JP2014198738A (ja) 2014-10-23
CA2807947A1 (en) 2012-02-16
CN103153968B (zh) 2016-02-03
DK2604595T3 (en) 2016-05-23
JP5765753B2 (ja) 2015-08-19
JPWO2012020749A1 (ja) 2013-10-28
AU2011290261B2 (en) 2014-11-06
WO2012020749A1 (ja) 2012-02-16
ZA201300920B (en) 2014-04-30
MX346367B (es) 2017-03-16
EP2604595A4 (en) 2014-04-23
BR112013002984B1 (pt) 2021-10-26
CA2807947C (en) 2018-06-19
CN103153968A (zh) 2013-06-12
EP2604595A1 (en) 2013-06-19
MX2013001542A (es) 2013-03-18

Similar Documents

Publication Publication Date Title
ES2572481T3 (es) Derivado de triacina y composición farmacéutica que tiene una actividad analgésica que contiene la misma
Nirwan et al. Thiazolidinones: Synthesis, reactivity, and their biological applications
KR870007137A (ko) 치환 피리딘술폰아미드 화합물, 이들을 함유하는 제초 조성물 및 이들 화합물의 제조 방법.
NO20081464L (no) 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
AR085585A1 (es) Vinil- y alquinilciclohexanoles sustituidos como principios activos contra estres abiotico de plantas
AU2016243631B2 (en) Methods of administering glutaminase inhibitors
AR043673A1 (es) Compuestos heterociclicos inhibidores no nucleosidos de la transcriptasa inversa i, preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del sida
RU2019103094A (ru) Гетероциклическое соединение и содержащее его средство для борьбы с вредными членистоногими
AU2198999A (en) Inhibition of raf kinase using substituted heterocyclic ureas
RU2008152065A (ru) Новое производное имидазола со спироциклической структурой в боковой цепи
RU2014113230A (ru) Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
HUP0302891A2 (hu) PDE4 izoenzimek inhibitoraiként alkalmazható éterszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
KR950704304A (ko) 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives)
RU2012129168A (ru) Производные оксазина
PH12012500643A1 (en) Novel phenol derivative
JP2010013443A5 (es)
NZ731337A (en) Compounds useful as inhibitors of atr kinase
WO2007059157A1 (en) Bisamide inhibitors of hedgehog signaling
MA30225B1 (fr) Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MX338041B (es) Inhibidores de demetilasa-1 especificos de lisina y su uso.
RU2014109363A (ru) Трициклические гетероциклические соединения и ингибиторы jak
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
ATE442356T1 (de) 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung